Oxybutynin Chloride
Product Images NDC 66336-604

6 FDA label images from Dispensing Solutions, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 66336-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ndc 66336-0604-xx (Ndc 66336 0604 Xx Impax)

Ndc 66336-0604-xx (Ndc 66336 0604 Xx Impax)
The packaging label for Oxybutynin Chloride ER 5 mg extended-release tablets by Dispensing Solutions, Inc. It includes dosing instructions, warnings, bulk source and manufacturing details from Impax Laboratories, and a barcode with sample lot and expiration placeholders. The label highlights that the product is prescription only and contains multiple small labels with drug information and a pharmacy logo.*
FDA Label Image

Chemical Structure (Oxybutynin 01)

Chemical Structure (Oxybutynin 01)
Chemical structure of oxybutynin chloride, displaying its molecular components including aromatic rings, ester and amine functional groups, and the hydrochloride salt component as indicated by HCl.*
FDA Label Image

Figure 1 (Oxybutynin 02)

Figure 1 (Oxybutynin 02)
Line graph comparing mean plasma R-Oxybutynin concentration (ng/mL) over 24 hours for Oxybutynin Chloride ER tablets 10 mg once daily and Oxybutynin 5 mg three times daily. The x-axis represents time in hours, and the y-axis shows concentration levels, with error bars indicating variability.*
FDA Label Image

Figure 2 (Oxybutynin 03)

Figure 2 (Oxybutynin 03)
A bar chart comparing the mean change in episodes per week from baseline between oxybutynin chloride extended-release tablets and placebo. The horizontal axis shows numerical values ranging from -40 to 40, with bars indicating the mean change and standard deviation for placebo treatment.*
FDA Label Image

Figure 3 (Oxybutynin 04)

Figure 3 (Oxybutynin 04)
A horizontal bar chart illustrating the mean change plus or minus standard deviation in episodes per week from baseline for oxybutynin and oxybutynin chloride extended-release (ER) tablets. The x-axis ranges from -40 to 40, showing the reduction in episodes per week.*
FDA Label Image

Figure 4 (Oxybutynin 05)

Figure 4 (Oxybutynin 05)
A horizontal bar chart illustrating the mean change with standard deviation in episodes per week from baseline, comparing oxybutynin treatment to a control. The x-axis ranges from -40 to 40 episodes per week, showing a negative change (reduction) for oxybutynin ER tablets relative to baseline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.